Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab

Review

Rohit Sud et al. Haematologica. 2008 Dec.

. 2008 Dec;93(12):1776-80.

doi: 10.3324/haematol.2008.000984.

No abstract available

Comment in

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome.
Martín A, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea. Martín A, et al. Haematologica. 2009 May;94(5):744. doi: 10.3324/haematol.2009.006452. Epub 2009 Mar 31. Haematologica. 2009. PMID: 19336744 Free PMC article. No abstract available.

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group). Martín A, et al. Haematologica. 2008 Dec;93(12):1829-36. doi: 10.3324/haematol.13440. Epub 2008 Oct 22. Haematologica. 2008. PMID: 18945747

1. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 1998;9:717–20. - PubMed
1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42. - PubMed
1. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–33. - PubMed
1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–5. - PubMed
1. Giesselbrecht CSN, Mounier N, et al. CORAL study R-ICE versus R-DHAP in relapsed patients with CD20 difuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not. first interim analysis on 200 patients. Blood. 2007;110:159a. - PubMed